Advancing the Treatment Paradigm for mCRPC: Insights into Combination Therapy and Future Directions : Episode 3
Opinion
Video
The PEACE-3 Trial
Author(s):
Panelists discuss how the PEACE-3 trial demonstrated meaningful clinical benefits with the combination of radium-223 and enzalutamide compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC), showing both improved radiologic progression-free survival and a significant overall survival advantage of 7.3 months.
Video Player is loading.
Video content above is prompted by the following:
- The PEACE-3 trial investigated whether the combination of radium-223 and enzalutamide (RAD-ENZ) improves cancer progression over enzalutamide alone in patients with mCRPC.
- Please discuss the significance of a 31% reduction in radiologic disease progression or death with the combination of RAD-ENZ.
- Discussing the secondary end point in a bit more detail, the overall survival, from 35 to 42.3 months, was statistically significant. What does this mean in clinical practice?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
The Growing Call for Combination Therapy in NMIBC Treatment
Optimizing NMIBC Treatment Through Sequencing and Patient Preference
Managing Abiraterone Intolerance: Alternative Dosing Strategies in Practice
Decision-Making and Multidisciplinary Counseling for Nodal Involvement on PSMA PET
Rethinking First-Line Treatments: Will BCG Continue to Be the Standard in NMIBC?
Related Content
